Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019)
Praxis Precision Medicines' quarterly Preferred Stock Liabilities came in at $121.1 million in Q4 2019.
Praxis Precision Medicines has reported Preferred Stock Liabilities for 1 years, with the latest figure at $121.1 million in Q4 2019.
- For the quarter ending Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $121.1 million; the trailing twelve-month figure through Dec 2019 stood at $121.1 million (changed N/A YoY), and the FY2019 full-year result was $121.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2019 stood at $121.1 million.
- The five-year high for Preferred Stock Liabilities was $121.1 million in Q4 2019, with the low at $121.1 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Praxis Precision Medicines | 10.11 Bn | 9.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 121.12 Mn |